Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Future of PV: Unmet Needs

February 9th 2024

Faculty offer insights into the future of PV management as well as unmet needs.

Dr Badar on Outcomes With Imetelstat in Lower-Risk MDS

February 7th 2024

Talha Badar, MBBS, MD, discusses key efficacy data with imetelstat from the phase 2/3 IMerge trial of patients with lower-risk myelodysplastic syndrome.

Dr Jain on Results From the COMMANDS Trial in Lower-Risk MDS

February 6th 2024

Akriti Jain, MD, discusses the outcomes of the phase 3 COMMANDS trial in transfusion-dependent lower-risk myelodysplastic syndromes.

Health Canada Slated to Review New Drug Submission for Momelotinib in Myelofibrosis

February 5th 2024

Health Canada will review the new drug submission seeking the approval of momelotinib in patients with myelofibrosis.

Monitoring Patients on Myelofibrosis Treatment

February 2nd 2024

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Treating Patients with Myelofibrosis and Anemia

February 2nd 2024

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Truong on the Rationale for Investigating ERK2 Substrate Binding Modalities in MPNs

February 2nd 2024

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Hobbs Highlights Key Research in Hematologic Malignancies at the 2023 ASH Annual Meeting

January 30th 2024

Gabriela Hobbs, MD, discusses the significance of key research across myeloproliferative neoplasms from the 2023 ASH Annual Meeting.

Targeted Agents and Combination Therapies May Open Doors in MDS Management

January 30th 2024

Talha Badar, MBBS, MD, discusses the FDA approval of ivosidenib for patients with myelodysplastic syndrome and the future management of this disease.

Momelotinib Approved in Europe for Myelofibrosis With Anemia

January 29th 2024

Momelotinib gets market authorization from the European Commission for patients with MPNs and disease-related splenomegaly or moderate to severe anemia.

Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023

January 26th 2024

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Role of Transplant in Myelofibrosis

January 26th 2024

Panel experts comment on the role of transplant in patients with myelofibrosis.

MDS Research Expands Treatment Options Across Disease Subsets

January 24th 2024

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.

Oral HMAs May Provide Safer and More Effective Treatment Options for MDS

January 23rd 2024

Guillermo Garcia-Manero, MD, spotlights the evolution of oral azacitidine- and decitabine-based regimens for MDS.

Dr Vincelette on MYC Expression in Myelofibrosis

January 20th 2024

Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.

MAJIC-PV: Clinical Implications in PV

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Frontline Tamibarotene Plus Venetoclax and Azacitidine Induces 100% CR Rate in SELECT-AML-1 Trial

January 16th 2024

Tamibarotene plus venetoclax/azacitidine elicited higher responses rates vs venetoclax/azacitidine in RARA-overexpressed acute myeloid leukemia.

GB2064 Displays Preliminary Efficacy, Tolerability in Myelofibrosis

January 16th 2024

GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

Polycythemia Vera: Treatment Goals and Options

January 12th 2024

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.